Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Anocca Receives GMP Certification for Cell Therapy Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Anocca Receives GMP Certification for Cell Therapy Mfg. Facility

Supports near-term path to the clinic and long-term strategy to advance franchises of precision targeted cell therapies for cancer.

By: Anthony Vecchione

Anocca AB, a TCR-T cell therapy company, has received a certificate of good manufacturing practice (GMP) compliance from the Swedish Medical Product Agency for its in-house cell therapy manufacturing facility.

The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises of precision targeted cell therapies for different cancers.

Anocca has built validated asset franchises against cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the pipeline.

Anocca’s lead franchise of TCR-T therapies target KRAS driver mutations which are responsible for extremely aggressive forms of cancer. These TCR-T products will be manufactured using a next-generation autologous approach that leverages non-viral gene editing to insert Anocca’s therapeutic TCR into a patient’s own T cells. Anocca will initiate its first clinical program in hard-to-treat solid tumor indications with TCR-T therapies across multiple KRAS mutation forms and patient segments.

“GMP certification of our in-house facility is a crucial milestone that allows us to confidently deploy the first of many TCR-T cell therapies into the clinic,” said Reagan Jarvis, Co-founder and CEO of Anocca, “The patients we are addressing have immense unmet medical need, and TCR-T is a therapeutic modality with the potential to transform patient outcomes.”

Hugh Salter, chief scientific officer, Anocca, said, “Our approach allows us to precisely map high-value but unexploited solid tumour targets such as KRAS and then fine-tune Anocca’s investigational TCR-T products against them. Next generation non-viral gene editing offers the precision and efficiency needed to scale out the manufacture of our broad TCR-T franchises.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics